Octagon Capital Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Octagon Capital Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-130,000	Closed	-$7.48M	–	45
2024 Q3	$7.48M	Sell	130,000 -130,000	-50%	-$7.02M	1.16%	23
2024 Q2	$10.8M	Hold	260,000	–	–	1.69%	16
2024 Q1	$15.9M	Buy	+260,000	New	+$11.7M	1.9%	16
2023 Q1	–	Sell	-53,333	Closed	-$1.9M	–	42
2022 Q4	$1.9M	Buy	+53,333	New	+$1.66M	0.3%	26

Other funds holding PRAX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Octagon Capital Advisors's PRAX Position: Q4 2024 in Review

Octagon Capital Advisors sold out of Praxis Precision Medicines (PRAX) in Q4 2024, closing a stake of 130,000 shares — an estimated $7.48M sold.

Octagon Capital Advisors first reported a position in PRAX in Q4 2022 and held it in 4 quarters. The position peaked at $15.9M in Q1 2024. 162 funds tracked by Wall St. Rank hold PRAX as of Q4 2024.

Octagon Capital Advisors reported no remaining Praxis Precision Medicines position as of Q4 2024 after selling out during the quarter.
Octagon Capital Advisors sold 130,000 Praxis Precision Medicines shares in Q4 2024, an estimated $7.48M.
Octagon Capital Advisors first reported a position in Praxis Precision Medicines in Q4 2022 and held it in 4 quarters.
Octagon Capital Advisors's Praxis Precision Medicines position peaked at $15.9M in Q1 2024.
162 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2024.

Based on Octagon Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.